Ophthotech Corp (OPHT) Tops Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Ophthotech Reports Second Quarter 2016 Financial and Operating Results
August 3, 2016 7:30 AM EDT- Conference Call and Webcast Today, August 3rd, at 8:00 a.m. ET
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the second quarter ended June 30, 2016 and provided an update on the Companys business and product development programs.
During the second quarter, we reached a significant milestone in our Fovista® program as we completed patient recruitment in our third Phase 3 trial of Fovista® in combination with Eylea® or Avastin®, said David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of... More
